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PPlatelet Reactivity After Clopidogrel
Treatment Assessed With Point-of-Care
Analysis and Early Drug-Eluting Stent Thrombosis
Dirk Sibbing, MD, Siegmund Braun, MD, Tanja Morath, MS, Julinda Mehilli, MD,
Wolfgang Vogt, MD, Albert Schömig, MD, Adnan Kastrati, MD, Nicolas von Beckerath, MD
Munich, Germany
Objectives The aim of this prospective trial was to assess whether platelet reactivity to clopidogrel assessed with multiple
electrode platelet aggregometry (MEA) correlates with the risk of early drug-eluting stent thrombosis (ST).
Background Studies using light transmission aggregometry (LTA) have shown that insufficient suppression of platelet reactiv-
ity to adenosine diphosphate (ADP) after clopidogrel treatment is associated with an increased risk of adverse
cardiovascular events after percutaneous coronary intervention (PCI). However, LTA is time- and labor-intensive
and inconvenient for the routine. A point-of-care assay with similar predictive power would be of great value.
Methods Between February 2007 and April 2008, a total of 1,608 consecutive patients with coronary artery disease and
planned drug-eluting stent implantation were enrolled. Before PCI, all patients received 600 mg clopidogrel.
Blood was obtained directly before PCI. The ADP-induced platelet aggregation was assessed in whole blood with
MEA on a Multiplate analyzer (Dynabyte, Munich, Germany). The primary end point was definite ST at 30 days.
Results The upper quintile of patients according to MEA measurements (n  323) was defined as clopidogrel low
responders. Compared with normal responders (n  1,285), low responders had a significantly higher risk of
definite ST within 30 days (2.2% vs. 0.2%; odds ratio [OR]: 9.4; 95% confidence interval [CI]: 3.1 to 28.4;
p  0.0001). Mortality rates were 1.2% in low versus 0.4% in normal responders (OR: 3.2; 95% CI: 0.9 to 11.1;
p  0.07). The composite of death or ST was higher in low versus normal responders (3.1% vs. 0.6%; OR: 5.1;
95% CI: 2.2 to 11.6; p  0.001).
Conclusions Low response to clopidogrel assessed with MEA is significantly associated with an increased risk of ST. Further
studies are warranted to evaluate the ability of MEA to guide antiplatelet therapy in patients undergoing
PCI. (J Am Coll Cardiol 2009;53:849–56) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.11.030m
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en patients undergoing percutaneous coronary intervention
PCI), dual antiplatelet treatment with aspirin and clopi-
ogrel is the therapy of choice for preventing thrombosis of
he treated vessels and subsequent ischemic events (1).
See page 857
espite this treatment, stent thrombosis (ST), a life-
hreatening event with serious clinical consequences (2,3), is
till feared to occur (4,5). Platelet reactivity to clopidogrel is
ariable (6), and prospective studies implementing different
rom the Deutsches Herzzentrum and 1. Medizinische Klinik rechts der Isar,
echnische Universität München, Munich, Germany. Material for platelet function
nalysis on the Multiplate device were provided free of charge from Dynabyte
Munich, Germany). Dr. Sibbing received speaker fees from Dynabyte. Dr. von
eckerath received speaker fees from Eli Lilly and fees for advisory board activities
rom Eli Lilly and Sanofi-Aventis. Dr. Kastrati received speaker fees from Eli Lilly,
anofi-Aventis, and Bristol-Myers Squibb.B
Manuscript received July 21, 2008; revised manuscript received October 9, 2008,
ccepted November 2, 2008.ethods of platelet function testing have reported that an
ttenuated response to clopidogrel is associated with an in-
reased risk of ischemic events after PCI including ST (7–13).
ight transmission aggregometry (LTA) has been the most
idely used technique in this setting. However, LTA mea-
urements are weakly standardized and time- and labor-
ntensive. Thus, LTA is not likely to be used as a matter of
outine in clinical practice. An association of high post-
reatment platelet reactivity with adverse events after PCI has
lso been reported in smaller study populations for a cartridge-
ased whole-blood point-of-care assay, which measures aden-
sine diphosphate (ADP)–induced agglutination of platelets
n fibrinogen-coated beads as an increase in light transmit-
ance (VerifyNow P2Y12 Assay, Accumetrics, San Diego,
alifornia) (7,14) and for a whole-blood flow-cytometry based
ssay that measures the phosphorylation of vasodilator-
timulated phosphoprotein (VASP), which depends on the
xtent of P2Y12 receptor inhibition (PLT VASP/P2Y12,
iocytex, Marseille, France) (9). A new point-of-care assay,
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Point-of-Care Analysis for Clopidogrel and ST March 10, 2009:849–56multiple electrode platelet ag-
gregometry (MEA), for rapid
and standardized assessment of
platelet function in whole blood,
has been developed recently (15).
The MEA implements the prin-
ciple of impedance aggregometry
with no need for blood centrifu-
gation and the ability to assess
platelet function in approxi-
mately 10 min. MEA assessed on
a device called the Multiplate
analyzer (Dynabyte, Munich,
Germany) is highly capable of de-
tecting the effect of clopidogrel treat-
ment, and the results of MEA cor-
relate well with LTA (16).
At present no data exist about
the value of MEA for predicting
ischemic events after PCI. More-
over, no prospective large-scale
trial has ever investigated the asso-
ciation of platelet reactivity to clo-
pidogrel with the occurrence of
both ischemic and bleeding events
simultaneously, and there is still
limited evidence for an association
of definite ST (17) with clopi-
dogrel low responsiveness.
The goal of this prospective trial
was to assess whether platelet re-
activity after clopidogrel treatment
and assessed with MEA correlates
ith the risk of definite ST and other ischemic as well as
leeding events after drug-eluting stent (DES) placement.
aterials and Methods
atients. Between February 2007 and April 2008, consecu-
ive patients with coronary artery disease (CAD) and planned
ES implantation in the 2 participating centers (Deutsches
erzzentrum München and I. Medizinische Klinik, Klinikum
echts der Isar, Technische Universität München, Munich,
ermany) were serially enrolled in this study. Inclusion in the
resent study did not preclude patients from inclusion into
ther clinical trials. Before PCI all patients received a loading
ose of 600 mg clopidogrel. Patients on clopidogrel mainte-
ance treatment received a 600-mg loading dose as well. The
ose was recommended to be given at least 2 h before
atheterization. However, a loading time 2 h did not pre-
lude study inclusion. Directly after diagnostic angiography
nd before PCI, all patients received an intravenous dose of
00 mg aspirin. Coronary interventions were performed ac-
ording to current standard guidelines (1). Intravenous antico-
gulant treatment with unfractionated heparin or bivalirudin
Abbreviations
and Acronyms
ADP  adenosine
diphosphate
AU  aggregation units
CAD  coronary artery
disease
CI  confidence interval
DES  drug-eluting stent(s)
HR  hazard ratio
LTA  light transmission
aggregometry
MEA  multiple electrode
platelet aggregometry
MI  myocardial infarction
NSTEMI  non–ST-segment
elevation myocardial
infarction
OR  odds ratio
PCI  percutaneous
coronary intervention
ROC  receiver-operator
characteristic
ST  stent thrombosis
STEMI  ST-segment
elevation myocardial
infarction
TIMI  Thrombolysis In
Myocardial Infarction
VASP  vasodilator-
stimulated phosphoproteinas administered with a dosing regimen of 140 U/kg body meight for unfractionated heparin and for bivalirudin with a
osing regimen of 0.75 mg/kg body weight for bivalirudin
irectly before PCI, followed by an intravenous infusion of
.75 mg/kg/h bivalirudin for the duration of the procedure. A
ubset of the patients received intravenous antiplatelet therapy
ith the glycoprotein IIb/IIIa inhibitor abciximab (0.25 mg/kg
f body weight bolus, followed by a 0.125 g/kg/min infusion
or 12 h) in addition to a reduced dose of heparin. After the
rocedure, patients were treated with 150 mg/day clopidogrel
n the hospital for 3 days and were discharged on a dual
ntiplatelet regimen of 75 mg/day clopidogrel and 100 mg
spirin (twice per day).
Patients were considered eligible for the study irrespective
f the clinical presentation at the time point of the PCI.
herefore, patients with an acute coronary syndrome, ST-
egment elevation myocardial infarction (STEMI) and non–
T-segment elevation myocardial infarction (NSTEMI) were
ncluded, as well as patients with stable CAD. Exclusion
riteria were contraindications to aspirin or clopidogrel treat-
ent and prior treatment with glycoprotein IIb/IIIa inhibitors
uring the 10 days before the PCI. The present study complies
ith the Declaration of Helsinki and was approved by the
nstitutional ethics committee. All patients gave written in-
ormed consent before entering the study.
lood sampling. Whole blood was obtained from the arte-
ial sheath of all patients after diagnostic angiography, before
CI, and at least 2 min after administration of intravenous
spirin. In all cases, blood samples were obtained before
dministration of intravenous PCI-related antithrombotic
reatment in the catheter laboratory. Blood was placed in
.0-ml plastic tubes containing the anticoagulant lepirudin (25
g/ml, Refludan, hirudin blood collection tubes, Dynabyte),
hich are recommended to be used for MEA (15). Blood
amples were kept at room temperature for at least 30 min
efore platelet function testing.
oint-of-care platelet function testing. The ADP-induced
latelet aggregation in whole blood was assessed with MEA
sing a new-generation impedance aggregometer called Mul-
iplate analyzer (Dynabyte) (15,16). Details of this method
ave been reported previously (16). In brief, after 1:2 dilution
f whole blood with 0.9% NaCl solution and stirring for 3 min
n the test cuvettes at 37°C, 6.4 mol/l ADP was added.
latelet aggregation was continuously recorded for 5 min.
mpedance with MEA is transformed to arbitrary aggregation
nits (AU) that are plotted against time (AU·min). Aggrega-
ion measured with MEA is quantified as AU and area under
he curve of arbitrary units (AU·min). All material used
ncluding ADP was obtained from the manufacturer
Dynabyte).
tudy end points and definitions. Definition of low re-
ponse to clopidogrel varies from study to study, and most of
he studies investigating this issue have used the upper 5% to
4% of patients (18) to define a cutoff value for low response.
e prospectively defined low response to clopidogrel by
etting a cutoff point at the upper quintile of MEA measure-
ents. This definition was also used for sample size calcula-
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March 10, 2009:849–56 Point-of-Care Analysis for Clopidogrel and STion. The primary end point of this study was the cumulative
ncidence of definite ST during a 30-day follow-up period.
efinite ST was defined according to the Academic Research
onsortium criteria (17) as the occurrence of an acute coronary
yndrome with either angiographic or pathological confirma-
ion of thrombosis. Secondary study end points were death
rom any cause, the composite of death from any cause or
efinite ST, and Thrombolysis In Myocardial Infarction
TIMI) major bleedings (19). We also assessed the incidence
f probable ST according to Academic Research Consortium
riteria (17), the composite of definite or probable ST, myo-
ardial infarction (MI), target lesion reintervention, ischemic
troke, intracranial hemorrhage, and TIMI minor bleeding
19). The diagnosis of MI was made according to TIMI
riteria (19) and based on new abnormal Q-wave appearance in
he electrocardiogram and/or an increase of the creatine
inase-MB value to 3 or more times the upper limit of normal.
fter PCI, cardiac markers were serially measured every 8 h for
he first 24 h after the procedure and then daily until discharge.
he diagnosis of ischemic stroke and hemorrhage required
onfirmation by computed tomography or magnetic resonance
maging of the head. All events were adjudicated by an event
djudication committee blinded to the platelet function status
f patients and not involved in the follow-up process.
ollow-up. Patients stayed in hospital for at least 2 days after
tudy inclusion. Patients were interviewed by telephone call
fter 30 days (7 days). Those patients with cardiac symptoms
ere seen in the outpatient clinic for complete clinical, elec-
rocardiographic, and laboratory check-up. Data of patients
ere collected and entered into a computer database by
pecialized personnel. All possible information from referring
hysicians, relatives, and hospital readmissions were entered as
ell. Source documentations were checked to ensure high-
uality data.
tatistical methods. In a large collaborative network meta-
nalysis, definite ST during the first 30 days after PCI was
bserved in 94 (0.7%) of 12,973 patients (20). Sample size
alculation for the present study was based on the assumption
hat the incidence of the primary end point (definite ST) was
.5% in clopidogrel responders (quintiles 1 to 4) and 2.5% in
onresponders (upper quintile). Choosing a power of 80% and
2-sided  value of 0.05, an overall sample size of at least 1,460
atients was required (nQuery advisor, version 7.0, Statistical
olutions, Cork, Ireland). To compensate for loss to follow-up
e aimed for the inclusion of 1,600 patients.
Variables are presented as mean  SD, counts (percent-
ges), and median with interquartile range. Categorical
ariables were compared using the chi-square test. The
olmogorov-Smirnov test was used to test for normal
istribution of continuous data. Normally distributed con-
inuous variables were compared with a 2-sided unpaired
test. A receiver-operator characteristic (ROC) curve anal-
sis was calculated to determine the ability of MEA to
istinguish between patients with and without definite ST
n the 30 days after the procedure. The optimal cutoff value
as calculated by determining the value for ADP-induced wlatelet aggregation in AU·min that provided the greatest
um of sensitivity and specificity. Survival analyses were
enerated using the Kaplan-Meier method, and the differ-
nces between groups were assessed by the log-rank test,
hich allowed the calculation of odds ratios (ORs) (95%
onfidence intervals [CIs]) associated with the 30-day
ncidence of the end points of interest. A Cox proportional
azards model was used to identify independent correlates
f the primary end point. The occurrence of definite ST was
efined as the dependent variable. Independent variables
ere platelet reactivity to clopidogrel and all variables shown
n Table 1 with significant differences (p  0.05) between
ormal and low responders. The hazard ratios (HRs) and
he corresponding 95% CIs were calculated.
For all statistical analyses, a value of p  0.05 was
onsidered significant. Analyses were performed using the
oftware package S-PLUS version 4.5 (Insightful Corp.,
eattle, Washington).
esults
uring the study period, a total of 1,608 CAD patients
reated with PCI were enrolled in this trial. Multiplate
easurements in the study population were not normally
istributed (1-sample Kolmogorov-Smirnov test; p 
.001). The median [interquartile range] value of ADP-
nduced platelet aggregation after administration of 600 mg
lopidogrel was 225 AU·min [141 to 369]. A broad range of
alues was observed (range 0 to 1,409 AU·min). The cutoff
alue for post-treatment Multiplate measurements defining
he upper quintile (20%) of patients was 416 AU·min.
ccording to this cutoff value, 323 patients were defined as
lopidogrel low responders. The remaining patients (n 
,285) were defined as clopidogrel normal responders.
The baseline characteristics of the study population are
hown in Table 1. Among low responders, the proportion of
iabetic patients, active smokers, as well as NSTEMI and
TEMI patients was significantly higher compared with
lopidogrel responders. In addition, low responders had a
ignificantly higher body mass index, a higher platelet
ount, a significantly lower ejection fraction, and a signifi-
antly shorter time from clopidogrel loading to blood
ampling compared with clopidogrel responders.
Angiographic and procedural characteristics of the study
opulation are shown in Table 2. A total of 2,809 lesions
ere treated in the entire study population. Variables were
ell balanced between the 2 groups. The large majority of
atients received a DES during the index procedure (98.0%
n normal responders vs. 98.2% in low responders; p 
.93). Only 23 patients (1.4%) had a follow-up shorter than
month.
schemic end points. The primary end point (definite ST)
ithin 30 days occurred in 10 (0.6%) patients. Six (60%) of
he 10 stent thromboses occurred within the first week after
CI (median 4.5 [1.3 to 8.3] days). Compared with patients
ith a normal response (n  1,285), low responders (n 
3
d
p
T
[
S
w
i
f
m
d
a
(
3
o
[
B
D xpresse
on myo
A
D
852 Sibbing et al. JACC Vol. 53, No. 10, 2009
Point-of-Care Analysis for Clopidogrel and ST March 10, 2009:849–5623) had a significantly higher risk of definite ST within 30
ays (7 [2.2%] vs. 3 [0.2%]; OR: 9.4; 95% CI: 3.1 to 28.4;
 0.0001). Characteristics of ST patients are shown in
able 3. The clopidogrel pre-treatment interval (median
interquartile range]) for patients with definite or probable
T was 5.5 [4 to 19] h versus 3.5 [2 to 19] h for patients
ithout ST (p  0.14). Figure 1A shows the cumulative
ncidence of the primary end point during the 30-day
aseline Characteristics of the Study Population
Table 1 Baseline Characteristics of the Study Population
Variable Overall (n  1,608) Norma
Age (yrs) 67.5 10.5
Women 374 (23.0)
Body mass index (kg/m2) 27.5 4.4
Ejection fraction (%) 54.5 11.3
Serum creatinine (mg/dl) 1.0 0.5
Diabetes mellitus 462 (29.0)
Insulin treatment 147 (9.1)
Oral treatment 231 (14.0)
Active smokers 216 (13.0)
Arterial hypertension 1,473 (91.6)
Hypercholesterolemia 1,122 (70.0)
Previous MI 507 (32.0)
Previous bypass surgery 232 (14.0)
Multivessel disease 1,369 (85.0)
CAD presentation
STEMI 40 (2.5)
Stable angina 1,075 (66.9)
Unstable angina 357 (22.2)
NSTEMI 136 (8.5)
Platelet count, 103/l 218 63
Time from loading (h) 4.0 [2.0–15.0]
Comedication
Aspirin treatment 1,593 (99.1)
Statin treatment 1,515 (94.2)
ata presented are mean  SD or n (%). Time from clopidogrel loading (h) to blood sampling is e
CAD  coronary artery disease; MI  myocardial infarction; NSTEMI  non–ST-segment elevati
ngiographic and Procedural Characteristics
Table 2 Angiographic and Procedural Characteristics
Variable Overall (n  2,809) Norma
Number of lesions per patient 1.7 1.0
Number of stents per lesion 1.2 0.5
Type of intervention
Stent placement 2,713 (96.6)
Balloon angioplasty 96 (3.4)
Lesion location
Left main 159 (5.7)
Left anterior descending 1,061 (37.8)
Left circumflex 755 (26.9)
Right coronary artery 777 (27.7)
Bypass graft 57 (2.0)
Vessel size, mm 2.8 0.6
AHA/ACC type B2/C 2,121 (75.5)
Chronic occlusion 193 (6.9)
Final diameter stenosis (%) 12.9 9.4ata presented are mean  SD or n (%).
AHA/ACC  American Heart Association/American College of Cardiology.ollow-up period in clopidogrel low responders versus nor-
al responders. Table 4 shows the number of events for
efinite ST and combined events for definite or probable ST
cross quintiles of MEA measurements. Mortality was 4
1.2%) in low versus 5 (0.4%) in normal responders (OR:
.2; 95% CI: 0.9 to 11.1; p 0.07). The composite of death
r ST was higher in low versus normal responders (10
3.1%] vs. 8 [0.6%]; OR: 5.1; 95% CI: 2.2 to 11.6; p 
onders (n  1,285) Low Responders (n  323) p Value
.7 10.4 66.7 10.9 0.12
87 (22.3) 87 (26.9) 0.08
.3 4.2 28.3 4.9 0.001
.9 10.9 53.2 12.6 0.03
.0 0.5 1.0 0.3 0.42
52 (27.4) 110 (34.1) 0.02
05 (8.2) 42 (13.0) 0.007
78 (13.9) 53 (16.4) 0.24
56 (12.1) 60 (18.6) 0.002
82 (92.0) 291 (90.1) 0.27
95 (70.0) 227 (70.0) 0.83
96 (30.8) 111 (34.4) 0.22
86 (14.5) 46 (14.2) 0.92
88 (85.0) 281 (87.0) 0.29
0.001
20 (1.6) 20 (6.2)
81 (68.6) 194 (60.1)
91 (22.6) 66 (20.4)
93 (7.2) 43 (13.3)
3 62 236 64 0.001
[2.0–15.5] 3.0 [2.0–7.0] 0.001
72 (99.0) 321 (99.4) 0.51
06 (93.9) 309 (95.7) 0.21
d as median [interquartile range].
cardial infarction; STEMI  ST-segment elevation myocardial infarction.
onders (n  2,221) Low Responders (n  588) p Value
.7 0.9 1.8 1.0 0.12
.2 0.5 1.2 0.6 0.15
0.63
47 (96.7) 566 (96.3)
74 (3.3) 22 (3.7)
0.97
26 (5.7) 33 (5.6)
38 (37.7) 223 (37.9)
93 (26.7) 162 (27.6)
20 (27.9) 157 (26.7)
44 (2.0) 13 (2.2)
.8 0.6 2.8 0.5 0.90
67 (75.1) 454 (77.2) 0.28
48 (6.7) 45 (7.7) 0.40
.8 9.3 13.3 10.1 0.27l Resp
67
2
27
54
1
3
1
1
1
1,1
8
3
1
1,0
8
2
21
4.0
1,2
1,2l Resp
1
1
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March 10, 2009:849–56 Point-of-Care Analysis for Clopidogrel and ST.001). Figure 1B shows the cumulative incidence of death
r ST in the 2 groups. Table 5 shows the entire clinical
utcome data for low versus normal responders at 30 days.
he cumulative incidence of target lesion reintervention,
schemic stroke, and the combined incidence of definite or
robable ST was significantly higher in low versus normal
esponders, whereas no differences were observed for prob-
ble ST alone and the incidence of MI in general. For the
ubgroup of patients with Q-wave infarction and MI24 h
ost-PCI, significantly more events were observed in low
ersus normal responders.
The optimal cutoff value according to ROC analysis to
redict the occurrence of 30-day ST was 468 AU·min. With
his cutoff value, the Multiplate assay had 70% sensitivity,
4% specificity, and an area under the ROC curve of 0.78
95% CI: 0.60 to 0.96, p  0.001).
redictors of ST. A Cox proportional hazards model was
sed to identify independent predictors for 30-day ST. The
odel included platelet reactivity to clopidogrel treatment
AU·min), as well as possible confounding variables of
atients’ baseline characteristics. These variables were dia-
etes mellitus, active smoking, body mass index, ejection
raction, platelet count, time from clopidogrel loading to
lood sampling, and CAD presentation (including STEMI,
STEMI, stable angina, and unstable angina, see Table 1).
In a first step, platelet reactivity (AU·min) to clopidogrel
as included as a continuous variable and calculations were
one for an absolute increase of 100 AU·min assessed with
EA. Results of this Cox proportional hazards model
howed that platelet reactivity to clopidogrel (per 100
U·min) was an independent predictor of 30-day ST (HR:
.38, 95% CI: 1.14 to 1.66; p  0.001). The only other
haracteristics of Patientsith Definite or Probable ST
Table 3 Characteristics of PatientsWith Definite or Probable ST
ST Patients
(Gender, Age [yrs])
MEA Value
(AU·min
Pre-Treatment
Interval (h)
Time to ST
(Days)
Definite ST
Patient #1 (male, 54) 1,196 12 2
Patient #2 (female, 64) 1,077 5 1
Patient #3 (female, 90) 965 4 0
Patient #4 (male, 68) 819 20 1
Patient #5 (male, 62) 606 6 7
Patient #6 (female, 67) 599 22 6
Patient #7 (male, 61) 468 2 29
Patient #8 (female, 85) 271 19 10
Patient #9 (female, 48) 244 2 8
Patient #10 (female, 74) 73 8 1
Probable ST
Patient #11 (male, 75) 988 2 2
Patient #12 (male, 65) 730 4 18
Patient #13 (male, 72) 276 4 6
Patient #14 (male, 71) 239 46 18
he pre-treatment interval in hours is the time interval from clopidogrel loading to blood sampling.
he time to ST is the time from the primary coronary intervention to the occurrence of ST.
AU  aggregation units; MEA  multiple electrode platelet aggregometry; ST  stent
hrombosis.ndependent predictor of 30-day ST was platelet countcalculated for an increase of 100 103/l in platelet count)
HR: 2.43, 95% CI: 1.44 to 4.09; p  0.001). The
emaining variables included for multivariate analysis were
ot found to be independent predictors of 30-day ST
p  0.18).
In a second step and similar to the primary analysis,
latelet reactivity to clopidogrel was regarded as a categor-
cal variable (low response or normal response) for the
ultivariate model. With this approach, low response to
lopidogrel assessed with MEA was also found to be an
ndependent predictor for the occurrence of ST (HR: 10.95,
5% CI: 2.31 to 51.99; p  0.003).
leeding end points. The cutoff value for post-treatment
EA measurements defining the lowest quintile of patients
as 124 AU·min. According to this cutoff value, 318
atients were defined as high-responders. For the lowest
uintile of patients (n  318), no significant increase in
IMI major bleeding was observed compared with quintiles
to 5 (4 [1.3%] vs. 9 [0.7%]; p  0.32). In addition, no
ignificant difference was observed for the incidence of
Figure 1 Kaplan-Meier Analysis
Kaplan-Meier analysis for the cumulative incidence of stent
thrombosis (A) and for the composite of death or stent thrombosis (B).
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Point-of-Care Analysis for Clopidogrel and ST March 10, 2009:849–56IMI minor bleedings (10 [3.1%] for high responders vs. 31
2.4%] for the remaining patients; p  0.45). A total of 2
ntracranial bleedings occurred in the study population.
lbeit being above the cutoff value defining the lowest
uintile of patients (124 AU·min), these 2 patients had
elatively low values of ADP-induced platelet aggregation
168 AU·min, 152 AU·min).
iscussion
his is the first prospective trial investigating the impact of
latelet reactivity to clopidogrel assessed with MEA on the
isk of early ST and other ischemic as well as bleeding events
fter PCI. It is the largest study to date showing that low
esponse to clopidogrel is associated with an increased risk
f drug-eluting ST, and it is the first study so far with
efinite ST (17) as the primary end point. For clopidogrel
ow responders, an approximately 11-fold increase in the
ncidence of 30-day ST was observed compared with normal
esponders. Importantly, the study also showed that low
esponse to clopidogrel is an independent predictor for the
ccurrence of ST. This finding was true regardless whether
U·min was included as a categorical or a continuous
ariable, whereas the latter may better reflect the biological
ackground of platelet hyperreactivity, which is a continuum as
ell. Importantly, we did not observe a gradual increase of
vents across quintiles but a significant accumulation of
tent thromboses in patients belonging to the upper quintile
f MEA measurements. In fact, an MEA value close to the
oundary for the upper quintile of patients (416 AU·min)
as also identified by ROC analysis (468 AU·min). Using
OC analysis, we observed that MEA had a strong predic-
ive value with an area under the curve of 0.78. Aside from
istribution of ST Across Quintiles
Table 4 Distribution of ST Across Quintiles
1st Quintile 2nd Quintile
Definite ST 1 0
Combined probable/definite ST 1 0
otal number of events for definite ST and combined events for definite or probable ST across quin
nd 416 AU·min.
Abbreviations as in Table 3.
linical Outcome
Table 5 Clinical Outcome
Ischemic Events, n (%) Normal Responders
Definite ST 3 (0.2)
Probable ST 2 (0.2)
Combined probable/definite ST 5 (0.4)
Death 5 (0.4)
Combined death/definite ST 8 (0.6)
Myocardial infarction 41 (3.2)
MI 24 h post-PCI 5 (0.4)
Q-wave MI 4 (0.3)
Target lesion reintervention 7 (0.5)
Ischemic stroke 2 (0.2)I  confidence interval; MI  myocardial infarction; OR  odds ratio; PCI  percutaneous coronary inteT, other ischemic events were also associated with low
esponse to clopidogrel, which underlines the predictive
alue of the Multiplate analyzer for the occurrence of
schemic events after PCI.
Different methods are currently used to assess platelet
unction (18). Among the most commonly used methods,
TA, VerifyNow, and MEA are functional assays (in
ontrast to VASP) that measure ADP-induced platelet
ggregation with different techniques (16,18). The LTA
nd VerifyNow assays are based on changes in light trans-
ission in a liquid phase after ADP stimulation, whereas
EA is based on the principles of impedance aggregom-
try. The LTA and the VASP assays are time-intensive,
equire skilled personnel, and are therefore not suitable for
linical practice. A point-of-care approach can only be
ealized with the VerifyNow and MEA assays, both of
hich are whole-blood methods. Although a correlation
xists between VerifyNow and MEA (21) and between
EA and LTA (16), it is obvious that these methods yield
imilar but not identical results. In this context, assessing
latelet function in whole blood (MEA and VerifyNow) has
ome advantages over LTA using platelet-rich plasma.
here is no need for centrifugation that can alter platelet
unction to separate platelets from other blood cells (22,23).
his enables an easy and fast assessment of platelet function
ith the possibility to decide on treatment regimens when
he patient is still in the catheter laboratory. In contrast to
TA or VerifyNow, in which aggregation occurs in a liquid
hase, aggregation in MEA takes place on surfaces. This is
imilar to in vivo conditions, in which platelet aggregation
akes place on surfaces as well, such as on ruptured plaques,
t sites of vascular injury, or on stent struts. The MEA
3rd Quintile 4th Quintile 5th Quintile p Value
1 1 7 0.003
2 2 9 0.001
cording to MEA measurements. The boundaries for MEA quintiles were as follows: 124, 192, 261,
ow Responders OR (95% CI) p Value
7 (2.2) 9.41 (3.11–28.44) 0.0001
2 (0.6) 4.00 (0.65–24.47) 0.13
9 (2.8) 7.26 (2.86–18.46) 0.0001
4 (1.2) 3.20 (0.92–11.10) 0.07
10 (3.1) 5.05 (2.19–11.64) 0.001
12 (3.7) 1.16 (0.61–2.21) 0.64
5 (1.5) 4.02 (1.28–12.63) 0.02
5 (1.5) 4.99 (1.53–16.29) 0.008
7 (2.2) 4.02 (1.53–10.58) 0.005
3 (0.9) 6.01 (1.25–28.88) 0.03tiles acLrvention; ST  stent thrombosis.
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March 10, 2009:849–56 Point-of-Care Analysis for Clopidogrel and STechnique is a relatively new one, and data on its clinical and
ethodical properties are still limited. Aside from a good
orrelation of MEA with the golden standard of LTA (16),
EA is capable of detecting the amount of platelet inhi-
ition achieved using different P2Y12 antagonists including
lopidogrel, cangrelor, and the active metabolites of clopi-
ogrel and prasugrel in varying doses (24,25).
Aside from the present study, no prospective study is
vailable that shows a significant association of low response
o clopidogrel and definite ST, the clinical end point with
he highest interest. The RECLOSE (Low Responsiveness
o Clopidogrel and Sirolimus- or Paclitaxel-Eluting Stent
hrombosis) trial (8) has shown that the cumulative inci-
ence of definite and probable ST was higher in clopidogrel
onresponders compared with responders. However, this
ifference was mainly driven by the high rate of probable ST
n the nonresponder group and no significant difference for
he incidence of definite ST was observed, which is in
ontrast to the results of our study. Other prospective
tudies using LTA did not focus on ST specifically but
efined combined primary end points including MI, stroke,
ardiovascular death, or target lesion revascularization (10,12,13).
mong them, the EXCELSIOR (Impact of Extent of
lopidogrel-Induced Platelet Inhibition During Elective Stent
mplantation on Clinical Event Rate) trial (10) was the first to
onvincingly show that platelet aggregation above the me-
ian was associated with an increased rate of ischemic
vents. However, a possible association of ST and low
esponse to clopidogrel was not reported specifically. In this
ontext, use of combined primary end points including MI
r target lesion revascularization implies the risk of assign-
ng a significant proportion of observed events to clopi-
ogrel low response, which in fact have other causes.
oncerning the incidence of MI in our study, we only
bserved significant differences for infarctions 24 h post-
CI. This finding may be attributed to the fact that the
tiology of immediate (24 h) MI—representing the ma-
ority of MIs in our study—is multifactorial (e.g., occlusion
f side branches, washout of myocardial enzymes in acute
oronary syndromes) and probably only to a minor extent
nfluenced by antiplatelet therapy.
Results of our study are based on the use of 1 single
oint-of-care assay, the Multiplate device. Recently, differ-
nt studies using the VerifyNow assay have convincingly
hown that high post-treatment platelet reactivity was
ssociated with ischemic events after PCI (7,14). Price et al.
7) showed in a homogenous population (n  380) regard-
ng the clopidogrel pre-treatment interval and the type of
tent used, that point-of-care measurements are associated
ith ischemic events after DES placement.
The 30-day incidence of definite ST in our study (0.6%) is
onsistent with a previous report (5) investigating 2,229 pa-
ients after DES implantation in which ST was observed in
.6% of patients at 30 days and with a large meta-analysis (n
2,973 patients) in which definite ST was reported to occur at
rate of 0.7% (20). Similar to the results of Iakovou et al. (5), ie observed that the majority of stent thromboses occurred
ithin the first week after the procedure. This emphasizes the
eed for early testing of platelet function; ideally before the
rocedure to intensify antiplatelet treatment if needed. Based
n our observations, we calculated that a total number of
pproximately 500 platelet function tests using the Multiplate
nalyzer would be needed to prevent 1 ST in the low-
esponder group (n 100) under the assumption that the risk
f ST would be reduced by 50% (from 2.2% to 1.1%) in this
roup of patients when an intensified or alternative antiplatelet
reatment is administered.
The predictive value of platelet function testing for
leeding events in PCI patients has never been investigated
efore. Here, we did not find a significant association of
igh response to clopidogrel treatment and the occurrence
f bleeding events. A trend was observed toward more
IMI major bleeding episodes in the high-responder sub-
roup of patients compared with the remaining patients
1.3% vs. 0.7%, respectively) and it is perceivable that an
ven larger trial would find a significant relationship be-
ween clopidogrel high response assessed with MEA and
leeding risk.
Large prospective studies to determine whether individ-
al guidance of tailored antiplatelet treatment based on the
esults of platelet function testing improves clinical outcome
n patients after coronary stent placement are still needed
26). The GRAVITAS (Gauging Responsiveness With A
erifyNow Assay-Impact On Thrombosis And Safety)
rial using the VerifyNow assay is currently on the way to
ddress this issue in larger study populations. In the future,
RAVITAS and other prospective large-scale trials should
etermine whether direct guidance of tailored antiplatelet
reatment based on platelet function testing could improve
he clinical outcome of patients after coronary stenting.
Based on the results of our study, MEA performed on a
ultiplate analyzer with all of the advantages of an easy-
o-use point-of-care assay is likely to be helpful for tailoring
ntiplatelet treatment to the needs of individual patients
reated with PCI. To address this issue specifically, a large
rospective clinical trial using the Multiplate analyzer is
eeded, in which patients defined as low responders are
andomized to intensified antiplatelet treatment using either an
ncreased clopidogrel maintenance dose or more potent
ntiplatelet drugs such as prasugrel. As soon as prasugrel
nd the other newly developed P2Y12 inhibitors are avail-
ble, assessing clopidogrel response may become mandatory
o avoid unnecessary stent thromboses related to clopidogrel
ow responsiveness.
tudy limitations. Herein we report clinical follow-up data
or a time period of 30 days after the procedure. Whether
ssessment of platelet function with MEA is also predictive
or the occurrence of long-term clinical events must to be
etermined separately. However, a follow-up period of 30
ays has several advantages. It is the period with the highest
isk of ST, and a 30-day follow-up interval attenuates the
nterference of drug noncompliance in the long term. In
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oint to detect a cause–effect relationship. In daily clinical
ractice, the clopidogrel pre-treatment interval is variable,
hich obviously affects the results of platelet function
esting. However, it is highly improbable that this had a
elevant impact on the results of our study for 2 reasons.
irst, the significant association of platelet reactivity to
lopidogrel and ST was maintained after adjustment for
ime from clopidogrel loading in the multivariate analysis.
econd, patients who suffered an ST had a relatively long
lopidogrel pre-treatment interval compared with patients
ithout ST. A limitation of the study is related to the low
umber of events that composed the primary end point,
espite the large number of patients included in this study.
his reflects the increased safety associated with current
CI but also underscores the need for larger studies to
orroborate present results. Results of this study are based
n measurements with MEA. Although we know that
EA measurements correlate with LTA (16) and the
erifyNow assay (21), we are unable to say how the results
f the present study can be extrapolated to other assays for
latelet function testing.
onclusions
low response to clopidogrel treatment assessed with
EA is significantly associated with an increased risk of
T. Further studies are warranted to evaluate the ability of
EA to guide antiplatelet therapy in patients undergoing
CI.
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